<DOC>
	<DOCNO>NCT00171314</DOCNO>
	<brief_summary>Post-menopausal breast cancer patient receive letrozole 2.5 mg daily treatment breast cancer randomize treatment group receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 month delay start zoledronic acid 4 mg IV 15-minute infusion every 6 month . Delayed start zoledronic acid initiate either Bone Mineral Density T-score -2 Standard Deviations either lumbar spine hip clinical fracture unrelated trauma asymptomatic fracture discover month 36 schedule visit . Letrozole 2.5 mg give daily 5 year .</brief_summary>
	<brief_title>The Use Zoledronic Acid Prevent Cancer-treatment Bone Loss Post-menopausal Women Receiving Adjuvant Letrozole Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Stage IIIIa breast cancer Postmenopausal Recent surgery breast cancer Metastatic disease Invasive bilateral disease Clinical radiological evidence exist fracture spine hip Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>letrozole</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>adjuvant</keyword>
	<keyword>postmenopausal</keyword>
</DOC>